{"type":"rich","version":"1.0","provider_name":"Transistor","provider_url":"https://transistor.fm","author_name":"Blood Cancer Talks","title":"Episode 65. Circulating Tumor DNA in DLBCL with Dr. Ash Alizadeh and Dr. David Russler-Germain","html":"<iframe width=\"100%\" height=\"180\" frameborder=\"no\" scrolling=\"no\" seamless src=\"https://share.transistor.fm/e/3df6104c\"></iframe>","width":"100%","height":180,"duration":3188,"description":"In this episode of Blood Cancer Talks, hosts Eddie, Ashwin, and Raj welcome two distinguished experts to explore the cutting-edge field of circulating tumor DNA (ctDNA) in B-cell lymphomas. Dr. David Russler-Germain, a lymphoma clinician from Siteman Cancer Centre at Washington University in St. Louis, returns as a familiar voice to the podcast audience. Joining him is Dr. Ash Alizadeh, the Moghadam Family Professor of Medicine, Oncology, and Hematology at Stanford University and leader of the Cancer Genomics Program at Stanford Cancer Institute. Dr. Alizadeh has been instrumental in advancing our understanding of lymphomagenesis and lymphoma genetics over the past two decades, pioneering multiple ctDNA techniques that are revolutionizing cancer care. Together, they discuss the transformative potential of ctDNA technology in B-cell lymphomas, particularly DLBCL, covering everything from the technical evolution of biomarker detection to groundbreaking clinical data that may reshape how we monitor and treat these aggressive cancers.\n \nKey Discussion Topics\n1. Genetic Heterogeneity in B-Cell Lymphomas\nComplex genetic landscape of DLBCL\nImplications for treatment strategies\nNeed for personalized approaches\n \n2. Clinical Need for ctDNA in Lymphoma\nWhy ctDNA is needed in aggressive lymphomas:\nCurative vs. non-curative treatment settings\nLimitations of current PET imaging\nAdditional prognostic information beyond imaging\nRisk stratification capabilities\nPotential to avoid overtreatment\nTherapy adaptation opportunities\n \n3. Challenges in Lymphoma MRD Assessment\nWhy lymphoma MRD is more complex than other hematologic malignancies:\nDifferences from acute leukemias, CLL, and myeloma\nTechnical challenges specific to lymphoid tumors\nLower circulating tumor burden compared to liquid tumors\n \n4. ClonoSEQ Technology\nMechanism: Immunoglobulin sequencing approach\nAdvantages: Established platform with regulatory approval\nDisadvantages: Limited sensitivity in peripheral blood,...","thumbnail_url":"https://img.transistorcdn.com/sqlYzk0Oxhchi1Lmft_9Md8dG97D7hyy2rwRG7COuc0/rs:fill:0:0:1/w:400/h:400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9zaG93/LzMyMDc4LzE2NTcz/MTQxMDUtYXJ0d29y/ay5qcGc.webp","thumbnail_width":300,"thumbnail_height":300}